Inato Partners with RealTime to Enhance Clinical Trial Site Selection and Patient Enrollment
核心洞察
Inato (搜索) and RealTime eClinical Solutions (搜索) have formed a strategic partnership to improve clinical trial site selection and subject enrollment by combining performance data with patient access insights.
The collaboration integrates RealTime-Devana (搜索)'s TrialAlign (搜索) site performance metrics with Inato (搜索)'s patient access information, expanding access to over 50 networks comprising more than 2,000 sites.
Participating sites will receive priority access to Inato (搜索)'s AI-driven patient pre-screening solution, which can reduce chart review times by up to 90 percent.
Inato (搜索) and RealTime eClinical Solutions (搜索) have announced a strategic partnership designed to revolutionize clinical trial site selection and patient enrollment processes. The collaboration merges RealTime-Devana (搜索)'s TrialAlign (搜索) site performance data with Inato's patient access information, providing pharmaceutical sponsors and contract research organizations (CROs) with enhanced insights for identifying high-performing, enrollment-ready sites.
Expanding Clinical Trial Network Access
The partnership significantly expands the available pool of qualified clinical trial sites by integrating two major networks. The collaboration enhances access to over 50 networks, comprising more than 2,000 sites currently utilizing RealTime-Devana (搜索) systems. These sites will be integrated with Inato (搜索)'s existing network of over 5,500 sites, creating a comprehensive platform for trial site selection.
The integration allows sponsors to view TrialAlign (搜索)'s up-to-date site metrics data directly within the Inato (搜索) platform, thereby expanding the pool of qualified sites available for clinical trials. This unified approach provides sponsors with comprehensive visibility into site performance and patient access capabilities.
Advanced Technology Integration
RealTime-Devana (搜索)'s business intelligence platform assists site networks in improving trial operations through the automation of study start-up processes, pipeline management, and extensive reporting and dashboard systems. The platform's capabilities are designed to streamline operational efficiency across participating sites.
As a result of this partnership, participating sites receive priority access to Inato (搜索)'s AI-driven patient pre-screening solution, which can decrease chart review times by as much as 90%. This technological advancement allows sites to showcase their patient access capabilities during feasibility evaluations, potentially accelerating the trial initiation process.
Industry Leadership Perspectives
Kourosh Davarpanah, co-founder and CEO of Inato (搜索), emphasized the partnership's alignment with the company's mission: "We built Inato to bring trials to all sites and patients. This partnership brings us a big step closer. By joining forces with RealTime's TrialAlign (搜索), we'll enable site networks to showcase proven patient access, activation speed, and enrollment performance to top sponsors, helping them secure the right trials for their patients."
Barry Lake, founder and president of RealTime-Devana (搜索), highlighted the strategic value of combining performance and access data: "Unbiased site performance data plus patient access data is the holy grail in terms of site selection and trial feasibility. Through this partnership with Inato (搜索), this holy grail can be delivered to sponsors and CROs. Together, we help sites put their best foot forward and enable sponsors to confidently partner with sites based on proven performance, engagement, and readiness."
Impact on Clinical Trial Efficiency
The partnership addresses critical challenges in clinical trial execution by providing sponsors with comprehensive data to make informed site selection decisions. By combining proven site performance metrics with real-time patient access information, the collaboration aims to reduce trial timelines and improve enrollment success rates.
The integration of these complementary platforms represents a significant advancement in clinical trial technology, offering the pharmaceutical industry enhanced tools for optimizing site selection and patient recruitment strategies.